Journals / Journal of Clinical and Experimental Investigations / 2018 / Cilt: 9 Sayı: 1

Investigation of Parvovirus B19 IgG and IgM antibodies with ELISA, distribution with regard to age groups and comparison with literature

Pages
30–33
Publication Date
2018-03-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In conclusion, parvovirus B19 IgG positivity was found similar with that in other countries.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Investigation of Parvovirus B19 IgG and IgM antibodies with ELISA, distribution with regard to age groups and comparison with literature Ayşe İnci, Aytül Çorbacıoğlu Esmer Objective: Human parvovirus is an un-enveloped, linear, single bundle DNA virus 18-26 nm in diameter which is common worldwide and causes an asymptomatic infection.
📊
Key Findings & Data:In this study, we aimed to determine parvovirus B19 sero-positivity rates, distribution according to age and contribute to epidemiologic data in our country.
💡
Conclusion & Impact:Conclusion: In conclusion, parvovirus B19 IgG positivity was found similar with that in other countries.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Parvovirus B19 · pregnancy · ELISA

Abstract

Investigation of Parvovirus B19 IgG and IgM antibodies with ELISA, distribution with regard to age groups and comparison with literature Ayşe İnci, Aytül Çorbacıoğlu Esmer Objective: Human parvovirus is an un-enveloped, linear, single bundle DNA virus 18-26 nm in diameter which is common worldwide and causes an asymptomatic infection. The most common clinical manifestation is erythema infectiosum, it may also lead to aplastic crisis, arthropathy, neutropenia, thrombocytopenia and fetal infections. In this study, we aimed to determine parvovirus B19 sero-positivity rates, distribution according to age and contribute to epidemiologic data in our country. Patients and Methods: Results of pregnant women who were admitted to Kanuni Suleiman Hospital between January 2015 and January 2017, examined for parvovirus B19 infection and whose parvovirus B19 IgG/IgM antibodies were examined with ELISA method were recorded from patient files. Parvovirus B19 IgM and parvovirus B19 IgG test results were retrospectively analyzed. parvovirus B19 IgM and parvovirus B19 IgG were examined with ELISA method in accordance with recommendations of the manufacturer. Results: A total of 156 pregnant women whose parvovirus B19 IgG/IgM antibodies had been analyzed were included in the study. While parvovirus B19 IgG was positive in 64.7% of the patients, parvovirus B19 IgM alone positivity was not detected in any women. parvovirus B19 IgG and IgM were positive in 3 women. parvovirus B19 IgG positivity was greatest above 40 years and minimum in 18-25 age group. Conclusion: In conclusion, parvovirus B19 IgG positivity was found similar with that in other countries. We consider that studies conducted with different groups and in different regions would contribute to epidemiologic data.

🔖

Cite This Article

İNCİ, A., ESMER, A. Ç. (2018). Investigation of Parvovirus B19 IgG and IgM antibodies with ELISA, distribution with regard to age groups and comparison with literature. Journal of Clinical and Experimental Investigations, Cilt: 9 Sayı: 1, 30–33. https://ajindex.com/articles/1001140

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Cohen B. Parvovirus B19: an expanding spectrum of disease. BMJ. 1995; 9;311:1549-52. 2. Işık N, Sabahoğlu E, Işık M, Anak S, Ağaçfidan A, Bozkaya E. Follow up of Patients Pre-Diagnosed as parvovirus B19 Infection. Turk Mikrobiyol Cem Derg. 2004;34:62-6. 3. Giorgio E, De Oronzo MA, Iozza I. et al. Parvovirus B19 during pregnancy: a review. J Prenat Med. 2010;4: 63–6. 4. Tolfvenstam T, Broliden K. parvovirus B19 infection. Semin Fetal Neonatal Med. 2009;14:218-21. 5. Enders M, Weidner A, Rosenthal T et al. Improved diagnosis of gestational parvovirus B19 infection at the time of nonimmune fetal hydrops. J Infect Dis. 2008;197:58-62. 6. Braham S, Gandhi J, Beard S, Cohen B. Evaluation of the Roche Light Cycler parvovirus B19 quantification kit for the diagnosis of parvovirus B19 infections. J Clin Virol. 2004;31:5-10. 7. Yetgin S, Elmas SA. Parvovirus-B19 and hematologic disorders. Turk J Hematol. 2010;27:224-33. 8.Jordan JA, Huff D, DeLoia JA. Placental cellular immune response in women infected with human parvovirus B19 during pregnancy. Clin Diagn Lab Immunol. 2001;8:288-92. 9. Dembinski J, Eis-Hubinger A, Maar J, Schild R, Bartmann P. Long term follow-up of serostatus after maternofetal parvovirus B19 infection. Arch Dis Child. 2003;88:219–21. 10. Désilets V, Audibert F; Society of Obstetrician and Gynaecologists of Canada. Investigation and management of non-immune fetal hydrops. J Obstet Gynaecol Can. 2013;35:923-38. 11. Türkdağı H,Özdemir M, Baykan M, Baysal B. Investigation of parvovirus B19 various age groups in central Anatolia Region. Mikrobiyol Bul. 2010;44:467-72. 12. Aktaş O, Aydın H, Uslu H. Serological prevalence of human parvovirus B19 in diseases or disorders related to different human body systems. Turk J Med Sci. 2016;46:368-73. 13. Colak D, Oğunc D, Aktekin M, Başustaoğlu AC, Gultekin M. Seroprevalence of parvovirus B19 antibodies in children between the ages 4-6 years in Ahatlı, Antalya. Klimik Dergisi 1998;2:61-2. 14. Sözen E, Bayram A, Onat AM, Balcı İ. The role of Herpesviridea and parvovirus B19 etiology of Ankylosing Spondylitis and Behçet’s Syndrome Turk J Infect 2008;22:75-8. 15. Us T, Cetin E, Kaşıfoğlu N, Akgun Y, Bal C. Investigation of the etiologic role of parvovirus B19 by immunologic and molecular methods in rheumatoid arthritis and systemic lupus erythematosus. Turkiye Klinikleri J Med Sci 2013; 33: 334–38. 16. Skjoldebrand-Sparre L, Fridell E, Nyman M,Wahren B. A prospective study of antibodies against parvovirus B19 in